Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2317 | Meditation and Anxiety Reduction Training Wiki | 1.00 |
| drug328 | Anxiety Reduction Training Wiki | 1.00 |
| drug2075 | Kundalini Yoga and Anxiety Reduction Training Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of the study is to compare the pharmacokinetics (PK) of bimekizumab when administered subcutaneously (sc) as 1x2 mL versus 2x1 mL, using a bimekizumab-safety syringe presentation or bimekizumab-auto-injector presentation, in healthy study participants.
Description: AUC: Area under the bimekizumab plasma concentration-time curve from time 0 (Day 1 predose) to infinity
Measure: Area under the plasma concentration-time curve from time zero to infinity (AUC) for a single dose bimekizumab (BKZ) Time: Baseline (Day 1 predose) at predefined time points (up to Day 140)Description: AUC0-t: Area under the bimekizumab plasma concentration-time curve from time zero (Day 1 predose) to the last quantifiable concentration
Measure: Area under the plasma concentration-time curve from time zero to last quantifiable concentration (AUC0-t) for a single dose bimekizumab (BKZ) Time: From Baseline (Day 1 predose) at predefined time points to the last quantifiable concentration (Day 140)Description: Cmax: Maximum observed plasma concentration
Measure: Maximum plasma concentration (Cmax) for a single dose bimekizumab (BKZ) Time: From Baseline (Day 1 predose) at predefined time points (up to Day 140)Description: An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Measure: Percentage of participants with at least one treatment-emergent adverse event (TEAE) from Baseline to end of Safety Follow-Up Time: From Baseline (Day 1) to end of Safety Follow-Up (up to Day 140)Description: A serious adverse event (SAE) is any untoward medical occurrence that at any dose: Results in death Is life-threatening Requires in patient hospitalization or prolongation of existing hospitalization Is a congenital anomaly or birth defect Is an infection that requires treatment parenteral antibiotics Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above
Measure: Percentage of participants with at least one treatment-emergent serious adverse event (SAE) from Baseline to end of Safety Follow-Up Time: From Baseline (Day 1) to end of Safety Follow-Up (up to Day 140)Description: Apparent terminal half-life, reported in units of days, as determined via simple linear regression (slope=-lambdaz) of natural log (ln) concentration versus time for data points in the terminal phase of the concentration-time curve. t1/2 is calculated as ln2/lambdaz.
Measure: Apparent terminal half-life (t1/2) Time: From Baseline (Day 1 predose) at predefined time points (up to Day 140)Description: tmax: time to reach maximum plasma concentration
Measure: Time of occurrence of the maximum observed concentration (tmax) of a single dose bimekizumab (BKZ) Time: From Baseline (Day 1 predose) at predefined time points (up to Day 140)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports